Immunome, Inc. IMNM
18.84 USD -1.47 (-7.24%)
Nov 4, 2026, 1:23 PM EST
18.47 Day range 22.77
14.64 52-week range 30.06
- YTD
- -12.29%
- 1 year
- +22.26%
- Market cap
- 2.22B
- EPS (ttm)
- -2.52
- Shares out
- 118.00M
- Forward P/E
- -8.26
- YTD return
- -12.29%
- 1-year return
- +22.26%
- Volume
- 1.66M
- Avg volume
- 1.30M
- Open
- 20.64
- Previous close
- 20.31
- Day's range
- 18.47 – 22.77
- 52-week range
- 14.64 – 30.06
- Beta
- 2.66
- Analysts
- Strong Buy
- Price target
- 35.33 (+87.5%)
- Earnings date
- Nov 5, 2026
30m +1.62 (+8.68%)
Key statistics
- Enterprise value
- 1.71B
- PEG ratio
- 0.00
- Price / book
- 4.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -143.66M
- Total cash
- 520.00M
- Total debt
- 4.74M
- Return on equity
- -64.03%
- Short % of float
- 17.02%
- 50-day average
- 22.26
- 200-day average
- 22.48
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.33 +87.5% upside
Now 18.84
- Target (low)
- 24.00
- Target (mean)
- 35.33
- Target (high)
- 40.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.5976.
Financials — quick view
IMNM Revenue — quarterly 0
IMNM Net income — quarterly -73.13M
IMNM EPS — quarterly -0.65
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.60365 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.51381 | -0.65 | -0.14 | -26.51% |
| May 12, 2026 | Mar 31, 2026 | -0.60 | -0.48 | +0.12 | +20.00% |
| Mar 3, 2026 | Dec 31, 2025 | -0.59017 | -0.75 | -0.16 | -27.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
| Aug 6, 2025 | Jun 30, 2025 | -0.52 | -0.50 | +0.02 | +3.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Wedbush | reit | Outperform | Outperform |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 1, 2026 | Stifel | init | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | init | — | Buy |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2026 | Truist Securities | main | Buy | Buy |
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunome.com
News
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know 
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates 
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference 
Immunome Says EMA Validates MAA For Varegacestat, Investigational, Oral, Once-Daily Gamma Secretase Inhibitor, For Treatment Of Adults With Desmoid Tumors 
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors 
Wedbush Reiterates Outperform on Immunome, Maintains $35 Price Target 
Immunome Showcases New Clinical Analyses Supporting Varegacestat's Profile In Desmoid Tumors At ESMO 2026 
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24
Your note
Sign in to keep a note on IMNM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARCHAS ISAAC | Director | Sale | Aug 11, 2026 | 0 |
| BIENAIME JEAN-JACQUES | Director | Purchase | Jun 4, 2026 | 43,415 |
| HIGGINS JACK | Officer | Conversion of Exercise of derivative security | Sep 10, 2026 | 59,250 |
| HORN KINNEY | Officer | Conversion of Exercise of derivative security | Aug 3, 2026 | 0 |
| LECHLEIDER ROBERT | Officer | Stock Award(Grant) | Jul 22, 2026 | 69,805 |
| ROSETT MAX | Chief Financial Officer | Stock Award(Grant) | Jul 22, 2026 | 101,287 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17.32% | 19,676,883 | 399.64M | Jun 29, 2026 |
| FMR, LLC | 14.96% | 16,987,553 | 345.02M | Jun 29, 2026 |
| Blackrock Inc. | 7.75% | 8,805,492 | 178.84M | Jun 29, 2026 |
| State Street Corporation | 4.84% | 5,494,625 | 111.60M | Jun 29, 2026 |
| Wellington Management Group, LLP | 4.59% | 5,210,216 | 105.82M | Jun 29, 2026 |
| Redmile Group, LLC | 4.32% | 4,911,590 | 99.75M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 6.32% | 7,179,563 | 145.82M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.32% | 4,903,773 | 99.60M | Aug 30, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.44% | 3,907,378 | 79.36M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3.26% | 3,703,461 | 75.22M | Jul 30, 2026 |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 3.25% | 3,692,941 | 75.00M | Jul 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.99% | 3,392,151 | 68.89M | Jun 29, 2026 |